StockData
GeneDx Holdings Corp. logo

GeneDx Holdings Corp. (WGS) stock

WGSNasdaqServices-Health ServicesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3058% above fair value
$51.02−1.35 (-2.58%)

Close on Nov 16, 2026Market cap $1.52BP/E –Yield –

GeneDx profit margin

Profit margin (net margin) is net income as a percentage of revenue.

GeneDx's profit margin for the twelve months ending Jun 30, 2026 was -23.4%. For fiscal 2025 it was -4.9%, against -17.1% the year before. The highest annual figure on record is -4.9% in fiscal 2025.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-4.9%+12.2
FY2024Dec 31, 2024-17.1%+69.7
FY2023Dec 31, 2023-86.8%+147.1
FY2022Dec 31, 2022-233.9%−118.3
FY2021Dec 31, 2021-115.6%+18.9
FY2020Dec 31, 2020-134.6%−119.4
FY2019Dec 31, 2019-15.1%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-15.5%−26.0
Q1 FY2026Mar 31, 2026-61.9%−54.4
Q4 FY2025Dec 31, 2025-14.6%−20.3
Q3 FY2025Sep 30, 2025-6.5%+4.3
Q2 FY2025Jun 30, 202510.5%+51.9
Q1 FY2025Mar 31, 2025-7.5%+24.9
Q4 FY2024Dec 31, 20245.7%+50.6
Q3 FY2024Sep 30, 2024-10.8%+68.5
Q2 FY2024Jun 30, 2024-41.4%+54.5
Q1 FY2024Mar 31, 2024-32.4%+109.0
Q4 FY2023Dec 31, 2023-44.9%+458.4
Q3 FY2023Sep 30, 2023-79.3%+13.9
Q2 FY2023Jun 30, 2023-95.9%+141.1
Q1 FY2023Mar 31, 2023-141.4%+1.2
Q4 FY2022Dec 31, 2022-503.3%−433.8
Q3 FY2022Sep 30, 2022-93.2%−169.0
Q2 FY2022Jun 30, 2022-237.1%−138.9
Q1 FY2022Mar 31, 2022-142.6%+156.2
Q4 FY2021Dec 31, 2021-69.5%+127.0
Q3 FY2021Sep 30, 202175.8%+222.4
Q2 FY2021Jun 30, 2021-98.2%+8.3
Q1 FY2021Mar 31, 2021-298.7%−240.9
Q4 FY2020Dec 31, 2020-196.5%–
Q3 FY2020Sep 30, 2020-146.6%–
Q2 FY2020Jun 30, 2020-106.5%–
Q1 FY2020Mar 31, 2020-57.9%–

More GeneDx figures

See a number that looks wrong?